ACAD
ACADIA Pharmaceuticals Inc
NASDAQ: ACAD · HEALTHCARE · BIOTECHNOLOGY
$20.32
+0.74% today
Updated 2026-10-28
Market cap
$3.27B
P/E ratio
8.57
P/S ratio
2.89x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$18 – $31
Volume
1.8M
ACADIA Pharmaceuticals Inc (ACAD) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$20.32
12-Month target
$21.13
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.5B | $0.5B | $0.7B | $1.0B | $1.1B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 8.57x (capped 25x) · Margin: 33.40%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.